Simphotek announces selection as a MedTech company
Simphotek has been selected as one of the showcase companies for the 2020-2021 NCI SBIR Investor Initiatives. As a MedTech company, it will be showcased at an investor conference Digital RESI on September 14-16, 2020!
Digital RESI – Three Day Conference
Life Science Nation is announcing “Premier Partnering” as a new service to augment the RESI Conference series. Premier Partnering Plus provides deep insight into the investors and strategic partners that regularly attend RESI conferences in search of assets to partner with and invest in. LSN, the creator of RESI, sells a world class investor and strategic partner database to scientist-entrepreneurs and fundraising CEOs, and now RESI attendees can get partial access to that data and review the deep profiles that come with this one-of-a-kind database as part of the RESI partnering experience. These investment mandates will be imported from the LSN Investor Platform that has more than 5,000 investors listed.
About Simphotek, Inc. Simphotek, Inc., a C-corp, is a leading-edge biotechnology company founded to create breakthrough personalized medical products to treat solid internal tumors, such as lung, mesothelioma, pancreatic, bladder, colon, brain, head and neck. It combines advanced computational methods and novel devices with non-radiative laser immuno-therapy to oblate cancer tissue with reduced side effects over traditional treatments including radiation and chemotherapy. In addition, it also releases tumor antigens activating both the innate and adaptive immune systems that can lead to systemic cancer treatment. Even more exciting, recently it has been combined with checkpoint inhibitors to show additional immunotherapy enhancement. In fact, the combination of Simphotek’s light therapy and checkpoint inhibitors shows greater therapeutic results than either one alone.
Simphotek collaborates with two leading designated cancer centers – the Hospital of the University of Pennsylvania and Roswell Park Comprehensive Cancer Center– to form a multi-disciplinary group of over twenty world-renowned oncologists, engineers, biologists, and radiation physicists all working together with one goal: to enable physicians to at least double/triple overall survival in treating solid tumors over current standard of care, such as radiation or chemotherapy. Combination with immuno-oncology (check point inhibitors) may lead to systemic cancer killing treatment. Simphotek's computational product uses advanced real time 3D simulation that may guide oncologists in delivering the required therapeutic dose to cancer patients during treatment, which cannot be done by any other system to date.
For further information regarding, Simphotek, Inc, please visit the Company’s website at www.simphotek.com.
